Efficacy and Safety of Salmeterol/fluticasone Combined with Montelukast versus Salmeterol/fluticasone in the Treatment of Cough Variant Asthma: A Meta-analysis / 中国药房
China Pharmacy
;
(12): 699-703, 2018.
Article
Dans Chinois
| WPRIM
| ID: wpr-704660
ABSTRACT
OBJECTIVE:
To evaluate the efficacy and safety of salmeterol/fluticasone combined with montelukast versus salmeterol/fluticasone in the treatment of cough variant asthma, and to provide reference for evidence-based reference in clinic.METHODS:
Retrieved from Cochrane library, PubMed, Chinese Journal Full-text Database, VIP and Wanfang database, randomized controlled trials (RCTs) about therapeutic efficacy (total response rate, marked improvement rate, cough disappearance time, 6-12 months recurrence rate) and safety (the incidence of ADR) of salmeterol/fluticasone combined with montelukast (trial group) vs. salmeterol/fluticasone (control group) in the treatment of cough variant asthma were included. Meta-analysis was performed by using Rev Man 5. 3 software after data extraction and quality evaluation with Cochrane system evaluation manual 5. 1. 0.RESULTS:
Totally 10 RCTs were included, involving 976 patients. Results of Meta-analysis showed the total response rate [RR=1. 22, 95%CI(1. 16, 1. 29), P<0. 001] and marked improvement rate [RR= 1. 38,95%CI(1. 22,1. 56),P<0. 001] of trial group were significantly higher than those of control group; the cough disappearance time was significantly shorter than control group [MD= - 3. 07, 95% CI (- 3. 54, -2. 59),P<0. 001],and 6-12 months recurrence rate was significantly lower than control group [RR=0. 24, 95%CI(0. 11, 0. 54), P<0. 001], with statistical significance. There was no statistical significance in the incidence of ADR between 2 groups [RR=1. 58, 95% CI (0. 99, 2. 51), P=0. 05].CONCLUSIONS:
The salmeterol/fluticasone combined with montelukast is better than of salmeterol/fluticasone in the treatment of cough variant asthma, but great importance should be attached to the occurrence of adverse events when using drug combination.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Type d'étude:
Essai clinique contrôlé
/
Guide de pratique
/
Revues systématiques évaluées
langue:
Chinois
Texte intégral:
China Pharmacy
Année:
2018
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS